evidence: There are fewer published data about the clinical impact of COVID-19 in people with leprosy. However, limiting health service access in PHC and competing for priority of hospitalization due to COVID-19 may increase the challenge of leprosy complication management such as leprosy reaction (type 1, type 2, and ENL) and DHS. Leprosy reactions are immune-mediated episodes of inflammation that are often self-limiting but may also be severe and prolonged (15). Leprosy reactions are the underlying cause of most disabilities in leprosy and, thus, many of the psychosocial consequences that may follow (16). DHS is a severe idiosyncratic drug reaction characterized by the clinical triad of fever, rash, and systemic involvement (most commonly of the liver and the hematologic system), which can cause severe organ dysfunction and manifest 4 to 6 weeks after the initiation of therapy (17). It is a rare life-threatening reaction globally with a range of incidence of 2% to 12% with a fatality rate of 9.9% (18). Due to the dominant HLA-B*13:01 carrier in Papuan ethnic groups, the incidence rate of DHS is highly reported among leprosy patients (11%) treated by dapsone as the significant component in MDT (19).